Сlinical and anamnestic features and their prognostic value in assessment of treatment effiiency of arterial hypertension with comorbidity
DOI:
https://doi.org/10.14739/2310-1237.2018.3.151678Keywords:
hypertension, obesity, telmisartan, prognosis, treatmentAbstract
Antihypertensive treatment leads to regression of left ventricular hypertrophy, reduces the incidence of cardiovascular complications and improves survival rates, and this occurs regardless of the degree of lowering of blood pressure (BP).
The aim of the study was to determinate the prognostic significance of clinical and anamnestic factors in the evaluation of effectiveness of therapeutic correction of arterial hypertension (AH) associated with obesity and diabetes mellitus by angiotensin II receptors blocker, telmisartan.
Material and methods. 135 patients were examined, diagnosed with AH stage I–II associated with obesity of 1–2 degrees (mean age 61.6 ± 6.7 years). Duration of study was 3 month. Chronic heart failure was no worse than II functional class by NYHA. Evaluation of prognostic properties of the studied factors was carried out using sequential hypothesis by Wald–Genkin, according to which all the indices were ranged with the subsequent determination of the prognostic coefficient (PC) and the general informativeness of the index (I). The groups were matched by sex, age, severity of the clinical condition, concomitant pathology. The control group consisted of 20 practically healthy persons of similar age and sex without signs of disease.
Results. In the study, the predictive value of clinical and anamnestic parameters of the effectiveness of antihypertensive treatment was analyzed. The results show that some clinical and anamnesis factors of the disease can be used to determine the telmisartan effectiveness in the treatment of hypertension with obesity. The most informative criteria (I > 1.0) are the duration (more than 11 years) of arterial hypertension, as well as the age of the patient and the presence of concomitant pathology, in particular type 2 diabetes and obesity.
Conclusions. Based on the obtained data about the value of clinical and anamnestic factors’ significance in assessing of the antihypertensive therapy in patients with co-morbid pathology, it is assumed that patients with hypertension duration of more than 11 years with concomitant obesity and type 2 diabetes and those older than 71 years require special tactics in the selection of antihypertensive therapy. And, most likely, such patients need more frequent adjustment of the doses of the drug.
References
Gubler E.V. (1987). Vyichislitelnye metody analiza i raspoznavanie patologicheskih protsessov [Computational methods of analysis and recognition of pathological processes]. M.: Meditsina, 294 s [in Russian].
Lifshits G.I. (2015). Prognosticheskiye markery klinicheskogo techeniya arterialnoy gipertonii i ostrogo infarkta miokarda. [Prognostic markers of the clinical course of arterial hypertension and acute myocardial infarction]. Nauchnyy almanakh (Meditsinskiye nauki), 11-4(13), 92-94. DOI: 10.17117/na.2015.11.04.092 [in Russian].
Machilskaya O.V. (2016). Faktory. opredelyayushchiye priverzhennost k lecheniyu bolnykh arterialnoy gipertenziyey (obzor literatury). [Factors determining adherence to the treatment of patients with arterial hypertension (literature review]. Kardiologiya i serdechno-sosudistaya khirurgiya, Vol.№3, 55-65. doi: 10.17116/kardio20169355-65. [in Russian].
Soldatenko I.V. (2010). Prohnostychno znachymi kryterii efektyvnosti kontroliu komorbidnoi z osteoartrozom arterialnoi hipertenzii. [Prognostically significant criteria for the control of comorbidity with osteoarthrosis of arterial hypertension]. Visnyk HNU im. V.N. Karazina: Seriia «Medycyna», 918, 20, 60-64 [in Ukrainian].
Tashchuk V.K., Denisyuk V.I., Khrebtiy G.I. (2014). Patohenetychni osoblyvosti terapii hipertonichnoi khvoroby u patsiientiv iz suputnim abdominalnym ozhyrinniam ta defitsytom masy tila [Pathogenetic features of therapy of hypertension in patients with concomitant abdominal obesity and body weight deficiency]. Bukovynskyi medychnyi visnyk - Bukovinsky medical bulletin, 18, 2 (70), 105- 108 [in Ukrainian].
Tomina O.Ye., Вichkova O.Yu. (2010) Prohnozuvannia efektivnosti kontroliu arterialnoho tysku pry arterialnii hipertenzii, sho komorbidna z vyrazkovoiu khvoroboiu Prediction of the effectiveness of control of arterial pressure in arterial hypertension that is comorbid with peptic ulcer. Visnyk HNU im. V.N. Karazina: Seriia «Medycyna», 918, 20, 77-82 [in Ukrainian].
Shelest A.N., Kovaleva Yu.A., Shelest B.A. (2016). Vlijanie ozhirenija na markery vospalenija u bol'nyh arterial'noj gipertenziej [Influence of obesity on markers of inflammation in patients with arterial hypertension]. Georgian Medical News, 255(6), 81-85 [in Russian].
Cortez D.N., Reis I.A., Souza D.A.S., Macedo M.M.L., Torres H.de C. (2015). Complications and the time of diagnosis of diabetes mellitus in primary care. Acta Paulista de Enfermagem, 28(3), 250-255. https://dx.doi.org/10.1590/1982-0194201500042.
Chun-Na J., Ming L., Jing-Ping S., Fang F., Yong-Na W., Cheuk-Man Yu, et al. (2014). The Prevalence and Prognosis of Resistant Hypertension in Patients with Heart Failure. PLoS One, 9(12), e114958. doi: 10.1371/journal.pone.0114958, PMCID: PMC4260939, PMID: 25490405.
Fuchs F.D., di Nicolantonio J.J. (2015). Angiotensin receptor blockers for prevention of cardiovascular disease: where does the evidence stand? Open Heart, 2, e000236. doi: 10.1136/openhrt-2014-000236.
Haass M., Kitzman D.W., Anand I.S., Miller A., Zile M.R., et al. (2011) Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I‐PRESERVE) trial. Circ Heart Fail, 4, 324–331
Katayama S., Hatano M., Issiki M. (2018). Clinical features and therapeutic perspectives on hypertension in diabetics. Hypertension Research, 41, 213–229. https://doi.org/10.1038/s41440-017-0001-5.
Kenchaiah S., Evans J.C., Levy D., Wilson P.W., Benjamin E.J., Larson M.G., et al. (2002). Obesity and the risk of heart failure. N Engl J Med, 347, 305–313. DOI: 10.1056/NEJMoa020245
Malek F. (2013) Arterial hypertension and chronic heart failure. Cor et Vasa, 55(3), e259-e263. https://doi.org/10.1016/j.crvasa.2013.04.002.
Nagarajan, V., Kohan, l, Hollande, E., Keeley, E.C., Mazimba, S. (2016). Obesity paradox in heart failure: a heavy matter. ESC Heart Fail, 3(4), 227–234. Published online 2016 Oct 31. doi: 10.1002/ehf2.12120 PMCID: PMC5107969 PMID: 27867523.
Nicoll, R., Ibrahimi, Y.Z.P., Olivecrona, G., Henein, M. (2016). Diabetes and Hypertension Consistently Predict the Presence and Extent of Coronary Artery Calcification in Symptomatic Patients: A Systematic Review and Meta-Analysis. Int. J. Mol. Sci, 17(9), 1481. Published online 2016 Sep 6. doi: 10.3390/ijms17091481, PMCID: PMC5037759, PMID: 27608015.
Paz, M.A., de-La-Sierra, A., Sáez, M., Barceló, M.A., Rodríguez, J.J., Castro, S., et al. (2016). Treatment efficacy of anti-hypertensive drugs in monotherapy or combination: ATOM systematic review and meta-analysis of randomized clinical trials according to PRISMA statement. Medicine (Baltimore), 95(30), e4071. Published online 2016 Jul 29. doi: 10.1097/MD.0000000000004071, PMCID: PMC5265817.
Ruschitzka, F., Taddei, S. (2012). Angiotensin-converting enzyme inhibitors: first-line agents in cardiovascular protection? Eur. Heart J., 33, 1996–1998.
Yang H., Wang Y., Negishi K., Nolan M., Marwick T.H. (2016). Pathophysiological effects of different risk factors for heart failure. Open Heart, 3, e000339‐2015‐000339. eCollection doi: 10.1136/openhrt-2015-000339.
Downloads
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (SeeThe Effect of Open Access).
